- Home
- ATHA vs IMNN Comparison
ATHA vs IMNN Comparison
Compare ATHA & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- IMNN
- Stock Information
- Founded
- ATHA 2011
- IMNN 1982
- Country
- ATHA United States
- IMNN United States
- Employees
- ATHA N/A
- IMNN N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- IMNN Health Care
- Exchange
- ATHA Nasdaq
- IMNN Nasdaq
- Market Cap
- ATHA 14.8M
- IMNN 12.1M
- IPO Year
- ATHA 2020
- IMNN 1985
- Fundamental
- Price
- ATHA $0.40
- IMNN $6.53
- Analyst Decision
- ATHA Hold
- IMNN Buy
- Analyst Count
- ATHA 3
- IMNN 2
- Target Price
- ATHA $0.50
- IMNN $182.61
- AVG Volume (30 Days)
- ATHA 133.3K
- IMNN 244.8K
- Earning Date
- ATHA 08-07-2025
- IMNN 08-05-2025
- Dividend Yield
- ATHA N/A
- IMNN N/A
- EPS Growth
- ATHA N/A
- IMNN N/A
- EPS
- ATHA N/A
- IMNN N/A
- Revenue
- ATHA N/A
- IMNN N/A
- Revenue This Year
- ATHA N/A
- IMNN N/A
- Revenue Next Year
- ATHA N/A
- IMNN N/A
- P/E Ratio
- ATHA N/A
- IMNN N/A
- Revenue Growth
- ATHA N/A
- IMNN N/A
- 52 Week Low
- ATHA $0.22
- IMNN $4.83
- 52 Week High
- ATHA $3.51
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- ATHA 53.29
- IMNN 40.89
- Support Level
- ATHA $0.38
- IMNN $6.17
- Resistance Level
- ATHA $0.41
- IMNN $7.21
- Average True Range (ATR)
- ATHA 0.02
- IMNN 0.51
- MACD
- ATHA -0.00
- IMNN 0.14
- Stochastic Oscillator
- ATHA 71.70
- IMNN 20.45
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).